Colorectal cancer test kit LCMNR01

oncologyfor NRAS mutationsclinical

NRAS Mutations Detection Kits are available in the following size, minimum order of 8 tests Detection of 16 mutations in NRAS codons 12, 13, 59, 61, 117 and 146 NRAS is a member of the RAS family of small GTPases and plays a central role in the MAPK signaling pathways. NRAS has been implicated in the pathogenesis of several cancers. NRAS mutations are particularly common in melanoma, phentermine hepatocellular carcinoma, myeloid leukemias, and thyroid carcinoma. In total, activating mutations in the NRAS genes occur in 13~25% of cutaneous melanomas, 1~6% of colorectal cancer and 1% of lung cancer, mainly in exons 2, 3 or 4. The mutation status of NRAS gene is relevant to drug resistance of non-small cell lung cancer treated with tyrosine kinase inhibitors. As a result, NRAS mutations detection supplies evidence for targeted clinical therapy of tumor patients. Intended Use NRAS Mutation Detection Kit is CE marked for IVD use in Europe. Technological Principles The kit uses novel, patented primers and probes to detect mutations in a real-time PCR assay. The mutant DNA is amplified accurately by the specific primers, and detected by the novel probes. Highly Specific primers and probes, and a highly validated procedure based on Taq DNA polymerase contribute to outstanding assay sensitivity and selectivity. Key Features and Benefits: Simple Procedure — only one step required for sample application, results obtained within 90 minutes. High sensitivity and accuracy — can detect 1-5% mutant DNA in a background of wild type genomic DNA. ADx-ARMs technology — employs a patented two-step PCR amplification procedure and novel fluorescent probe design.